Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 298 entries
View as:

Testing the Effect of Mindfulness for Prostatectomy Outcomes

Phase: N/A Priority: Normal
NCT ID: NCT04727710 Org: User:
Start: 08/26/20 End: 08/26/20 Due: 08/26/21

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Phase: N/A Priority: Normal
NCT ID: NCT02400190 Org: User:
Start: 05/27/15 End: 05/31/26 Due: 05/31/27

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04574856 Org: User:
Start: 11/04/20 End: 10/31/25 Due: 10/31/26

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05183126 Org: User:
Start: 03/28/22 End: 12/31/25 Due: 12/31/26

Genomics in Michigan Impacting Observation or Radiation

Phase: N/A Priority: Normal
NCT ID: NCT02783950 Org: User:
Start: 01/17/17 End: 04/02/24 Due: 04/02/25

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT02037230 Org: User:
Start: 01/31/14 End: 08/31/18 Due: 08/31/19

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00230451 Org: User:
Start: 11/30/97 End: 07/31/08 Due: 07/31/09

Sleep Coach: A Mobile App to Address Insomnia Symptoms Among Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT04827459 Org: User:
Start: 05/12/21 End: 08/08/22 Due: 08/08/23

Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00176813 Org: User:
Start: 03/31/03 End: 11/30/06 Due: 11/30/07

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT03135171 Org: User:
Start: 07/26/17 End: 03/20/20 Due: 03/20/21

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04431635 Org: User:
Start: 06/15/20 End: 11/14/23 Due: 11/14/24

Companion Pharmacogenetic Study to UMCC 9900/9901

Phase: N/A Priority: Normal
NCT ID: NCT00146029 Org: User:
Start: - End: - Due: -

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00141726 Org: User:
Start: 10/31/03 End: 02/28/09 Due: 02/28/10

Evaluating a Tailored Cognitive Behavioral Therapy for Adolescent and Young Adult Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04773197 Org: User:
Start: 11/30/20 End: 08/03/21 Due: 08/03/22

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00148070 Org: User:
Start: 03/31/99 End: 02/28/06 Due: 02/28/07

A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01661114 Org: User:
Start: 07/31/11 End: 03/31/16 Due: 03/31/17

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00726180 Org: User:
Start: 07/31/08 End: 10/31/10 Due: 10/31/11

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06580054 Org: User:
Start: 03/05/25 End: 03/01/30 Due: 03/01/31

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Phase: N/A Priority: Normal
NCT ID: NCT04518748 Org: User:
Start: 09/16/20 End: 11/30/28 Due: 11/30/29

A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01522937 Org: User:
Start: 10/31/09 End: 11/30/15 Due: 11/30/16

Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00573378 Org: User:
Start: 09/30/07 End: 12/31/15 Due: 12/31/16

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04140162 Org: User:
Start: 10/05/20 End: 05/02/26 Due: 05/02/27

A Study Using Cone Beam CT for Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01661062 Org: User:
Start: 01/31/09 End: 03/31/16 Due: 03/31/17

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00151047 Org: User:
Start: 03/31/03 End: 10/31/07 Due: 10/31/08

Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

Phase: N/A Priority: Normal
NCT ID: NCT00904345 Org: User:
Start: 04/30/09 End: 12/31/20 Due: 12/31/21